The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as first-line cytotoxic treatment.
Andreas Schneeweiss
Consultant or Advisory Role - Roche
Honoraria - Roche
Marcus Schmidt
Consultant or Advisory Role - Roche
Stock Ownership - Roche
Honoraria - Roche
Frank Gerhard Foerster
No relevant relationships to disclose
Matthias Geberth
No relevant relationships to disclose
Hans Tesch
Consultant or Advisory Role - Roche
Honoraria - Roche
Peter Klare
No relevant relationships to disclose
Claudia Schumacher
No relevant relationships to disclose
Wiebke Hollburg
No relevant relationships to disclose
Ulrike Soeling
No relevant relationships to disclose
Bahriye Aktas
No relevant relationships to disclose
Andreas Kutscheidt
No relevant relationships to disclose
Sherko Kümmel
Consultant or Advisory Role - Roche
Research Funding - Roche